Chronic analgesia blunts COX-2/PGE2–driven hormesis, accelerating epigenetic aging

Hypothesis

Long‑term use of NSAIDs and opioids suppresses physiological pain signaling that normally activates a low‑grade COX‑2/PGE2 hormetic cascade. This cascade stimulates autophagy, NAD⁺‑dependent sirtuin activity, and transient NF‑κB pulses that promote DNA repair and mitochondrial quality‑control. When pharmacologically muted, cumulative cellular damage accrues faster, reflected in accelerated epigenetic aging (e.g., GrimAge acceleration) and increased frailty risk.

Mechanistic Rationale

• COX‑2–derived PGE2 binds EP2/EP4 receptors, raising cAMP and activating PKA‑CREB signaling, which up‑regulates BNIP3‑mediated mitophagy and SIRT1 deacetylation of PGC‑1α.
• Episodic PGE2 spikes also trigger a brief, protective NF‑κB pulse that induces HSP70 and FOXO3 transcription without sustaining the chronic inflammatory secretome.
• Chronic NSAID inhibition of COX‑2 removes these pulses, shifting NF‑κB toward a persistent, SASP‑driving state and reducing autophagic flux.
• Opioid‑mediated μ‑receptor signaling similarly dampens glial COX‑2 expression in the spinal cord, attenuating the same peripheral hormetic loop.

Testable Predictions

1. In a cohort of adults aged 50‑80 with ≥6 months of daily NSAID or opioid use, GrimAge acceleration will be significantly higher than in matched controls after adjusting for baseline pain severity, comorbidities, and lifestyle covariates.
2. The magnitude of GrimAge acceleration will correlate negatively with serum PGE2 metabolites (13,14‑dihydro‑15‑keto‑PGE2) and positively with circulating SASP factors (IL‑6, IL‑8, MCP‑1).
3. Administration of a low‑dose, peripherally restricted EP2 agonist (e.g., butaprost) to analgesic‑treated mice will restore autophagic flux (LC3‑II/I ratio) and reduce p16^INK4a^ expression in liver and muscle compared with vehicle.
4. Wearable‑derived HRV and nocturnal respiratory variability will mediate the relationship between analgesic burden and epigenetic age, reflecting diminished recovery capacity.

Falsifiability

If longitudinal analysis shows no difference in GrimAge acceleration between chronic analgesic users and non‑users, or if EP2 agonism fails to rescue autophagy biomarkers in vivo, the hypothesis is refuted. Conversely, demonstration that analgesic cessation normalizes epigenetic age trajectories would further support the causal role of suppressed pain‑signaling hormesis.

Implications

Reframing analgesia as modulation—rather than abolition—of nociceptive signaling could lead to dosing strategies that preserve beneficial COX‑2/PGE2 pulses while mitigating nociceptive suffering, thereby uncoupling short‑term pain relief from long‑term biological aging.